MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 11:07:31 2024-06-27 am EDT | ||
| 3.905 EUR | -2.50% |
|
| 1 month | +34.89% | ||
| 3 months | +58.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 3.905 | -2.50% |
| 24-06-26 | 4.005 | -5.65% |
| 24-06-25 | 4.245 | +13.05% |
| 24-06-24 | 3.755 | -1.31% |
| 24-06-21 | 3.805 | -2.56% |
Real-time Euronext Paris
Last update June 27, 2024 at 11:07 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| R05NB | |
| ISIN | NLBNPNL2P6P5 |
| Date issued | 2024-03-22 |
| Strike | 710 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.335 € |
|---|---|
| Lowest since issue | 1.72 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,003
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.45%
- Stock Market
- Certificates
- R05NB Certificat
